Belluscura PLC Enters Joint Venture for Wound Care Innovation

Belluscura PLC (GB:BELL) has released an update.

Belluscura PLC has announced a joint venture with Separation Design Group and a major medical device company to develop oxygen-based wound care solutions, focusing on continuously diffused oxygen therapy. This collaboration positions Belluscura to capitalize on the growing $22.5 billion wound care market by leveraging its expertise in oxygen technology and the partner’s distribution capabilities. The initial clinical study is set to begin in early 2025 outside the U.S., marking a significant step in addressing hard-to-heal wounds.

For further insights into GB:BELL stock, check out TipRanks’ Stock Analysis page.